《大行》瑞銀亞太區重點推薦股票名單(表)
瑞銀發表報告,列出亞太區最新重點推薦股票名單,近日新納入新加坡新科工程(STEG.SI)及南韓SK海力士(000660.KS),剔出印尼Bank Mandiri:
股份│投資評級│目標價
騰訊(00700.HK)│買入│720港元
康方生物(09926.HK)│買入│224.3港元
怡和(JARD.SI)│買入│67.2美元
澳洲NEXTDC(NXT.AX)│買入│21.45澳元
澳洲Challenger(CGF.AX)│買入│9.3澳元
日本Asahi Intecc(7747.JP)│買入│3,490日圓
日月光(3711.TW)│買入│189元新台幣
日本東洋水產(2875.JP)│買入│11,700日圓
南韓SK海力士(000660.KS)│買入│394,000韓圜
新加坡新科工程(STEG.SI)│買入│10坡元
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.